Haemonetics ends its 2015 fiscal year in the red, posting a loss for the 4th quarter on uncertainty in Russia, currency fluctuations and restructuring costs.
Haemonetics (NYSE:HAE) finished out its 2015 fiscal 4th quarter in the red, hammered by a U.S. market shift that affected its blood center business, uncertainty in Russia, currency fluctuations and restructuring.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1EzKGPG
Cap comentari:
Publica un comentari a l'entrada